Exclusive Online Content
Spherix Global Insights Expands Therapeutic Area Coverage Into Hematology
Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth…..
CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation
CordenPharma and Certest have signed a partnership agreement on May 7, 2024, which aims to add ionizable lipids to CordenPharma’s complex LNP formulation services, the missing….
Vetter Announces Plans to Expand its Capacity in the US & Germany
The move will effectively double the capacity of Vetter Development Services in the US and provide ample space for future expansion opportunities…..
Gerresheimer to Acquire Blitz LuxCo Sarl, the Holding Company of the Bormioli Pharma Group
Gerresheimer underpins leading market position as a full-service provider for the pharmaceutical and biotech industries….
SCHOTT Pharma & KORU Medical Systems Collaborate to Advance Large-Volume Subcutaneous Infusion
SCHOTT Pharma and KORU Medical Systems are joining forces to offer a high volume subcutaneous drug infusion solution…..
Biolojic Design Enters Multi-Target Drug Discovery Collaboration With Merck KGaA
Merck KGaA, Darmstadt, Germany, will leverage Biolojic Design’s AI capabilities to create potential best-in-class multi-specific antibodies that uniquely modulate biology….
Longeveron Announces Contract Development & Manufacturing Business & First Contract
Longeveron Inc. recently announced the launch of its contract development and manufacturing business at the company’s 15,000-sq-ft state-of-the-art Good Manufacturing Practice (GMP) facility. This facility contains….
Aeterna Zentaris & Ceapro Complete Merger Transaction
Aeterna Zentaris Inc. and Ceapro Inc. recently announce the successful completion and closing of their all-stock merger of equals transaction (the Transaction), which was previously announced by….
Jeito Capital Announces Acquisition by Merck & Co. of its Portfolio Company EyeBio for a Potential Value of $3 Billion
This acquisition reflects the significant clinical progress achieved with Restoret, EyeBio’s novel late-phase candidate for diabetic macular edema, as well as….
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Skinvisible Pharmaceuticals, Inc. recently announced a major advancement in the battle against obesity. The company has achieved a significant milestone by officially filing a provisional patent application covering formulations that….
Evonik Drives Sustainable Biosurfactant Revolution With Inauguration of New Facility in Slovakia
First facility worldwide to manufacture industrial-scale rhamnolipid biosurfactants; huge potential in personal care, cleaning, coatings, animal nutrition, agriculture, and many other applications….
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
ProBioGen recently announced a pivotal collaboration with ModeX Therapeutics an OPKO Health Company dedicated to combating cancer and infectious diseases with cutting-edge….
Secarna Pharmaceuticals & Orbit Discovery Enter Collaboration to Discover & Develop Peptide-Conjugated Targeted Antisense Oligonucleotide Therapeutics
New platform capabilities extend the reach of Secarna’s antisense approaches, potentially offering new treatment options for a wider range of diseases….
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei Corp. recently announced it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of….
Agios Announces $905-Million Purchase Agreement for Vorasidenib Royalty
Agios Pharmaceuticals, Inc. recently announced it has agreed to sell its rights to its 15% royalty on potential US net sales of Servier’s vorasidenib to….
GlycoNex & PrecisemAb Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy
GlycoNex to advance development of novel pro-antibody cancer drugs that enhance tumor suppression while minimizing off-site binding to healthy tissues to improve safety and tolerability….
Amphista Therapeutics Unveils New Differentiated Mechanism of Action for BRD9 Degradation
Amphista’s bifunctional BRD9 degraders selectively induce BRD9 to DCAF16 proximity and serve as molecular glues, leading to strong and rapid degradation of BRD9….
Alvotech & Dr. Reddy’s Enter Commercialization Collaboration
Alvotech and Dr. Reddy’s Laboratories SA recently announced the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to….
Sana Biotechnology Highlights Novel In Vivo Preclinical Data Showing Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-Based Neurodegenerative Conditions
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice….
Premium Cell Culture Ingredients From Actylis
Download the Actylis Cell Culture Ingredients brochure to discover our product list or ask for a sample of a specific product…..
